MA-QUANTORI
20.7.2021 12:02:11 CEST | Business Wire | Press release
Quantori, a leading data science and digital transformation services company for the life sciences and healthcare sectors, today announced the appointment of Sean Murphy as Vice President of Client Services, effective immediately. Sean will oversee Quantori’s global network of IT professionals providing world-class software engineering and data analytics services to top biopharma and healthcare companies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210720005589/en/
“Sean has a strong track record of leading cross-functional teams to deliver innovative digital IT solutions that support a seamless digital transformation experience,” said Richard Golob, CEO of Quantori. “As we enter our next phase of growth, we are thrilled to welcome Sean aboard to ensure delivery of cost-effective, high-quality data science and software engineering services.”
Sean has held various leadership positions at AstraZeneca and Thermo Fisher Scientific, where he focused primarily on R&D IT and Cloud and Digital Transformations. At AstraZeneca, Sean designed, developed, and led the Application Lifecycle Services organization, a world-class software engineering team that delivers quality products and services throughout AstraZeneca. He also was instrumental in establishing captive offshore development centers for AstraZeneca.
Most recently, Sean served as Vice President at General Electric, where he was the Technology Leader for the business and digital transformation of corporate systems. He focused predominately on the implementation of the enterprise SaaS solution Workday across all General Electric businesses.
Sean received his B.S. degree in Business Administration from the University of New Hampshire and his M.Sc. degree in Management with a specialization in Biopharmaceutical Leadership from Emmanuel College. He currently serves as a board member of the United Nations Association of Greater Boston and has served as a board member of the Society for Information Management of Boston and Newton Girls Soccer.
“I’m excited to join the highly impressive Quantori leadership team to help deliver nextgen data science and software solutions that provide immediate value for our clients,” according to Sean. “While at AstraZeneca, I had the pleasure of working with some of the professionals who are now Quantori’s leaders. They were the only service providers who truly understood the drug development process and the scientific problems we were trying to solve. I was so impressed with their performance and ability to deliver that I wanted to join the team!”
Quantori’s executive leadership boasts a rich history in the life sciences and healthcare IT industry. CEO Richard Golob, Chief Scientific Officer Yuriy Gankin, Ph.D., and Chief Technology Officer Vitaliy Aronov have successfully joined forces for more than two decades to deliver award-winning software engineering and data analytics services to top pharmaceutical companies and research organizations around the globe. They previously cofounded GGA Software Services, which was acquired by EPAM Systems in 2014. Golob built EPAM’s Life Sciences Business Unit into the fastest growing unit at the company.
“What we’ve experienced over the past year is that our clients require a versatile digital IT services provider that understands their needs for scalability and flexibility and has deep domain and data science knowledge, and Quantori checks all these boxes,” said Yuriy Gankin, Chief Scientific Officer at Quantori. “Sean’s background in helping organizations navigate the digital revolution will be invaluable in helping us fulfill our mission to empower our clients to achieve their strategic business goals.”
Quantori’s global headquarters are located in Cambridge, Massachusetts, with additional offices in London, U.K., St. Petersburg, Russia, and Tbilisi, Georgia. The company serves leading research institutions and biopharma organizations, including Bruker, The Jackson Laboratory, Perkin Elmer, and Takeda. Quantori’s team is currently more than 400 professionals, and the company is actively seeking qualified experts globally to keep pace with its rapid growth. For more information, please visit www.quantori.com or email info@quantori.com .
“The robust software engineering, scientific informatics and data science capabilities that Quantori offers have enabled us to achieve our IT strategy by harnessing the power of innovative digital technologies,” said Scott Thomas, Vice President of Information Technology for the LGC Genomics Division. “The COVID-19 pandemic has significantly increased demand for genomic analysis, and Quantori’s digital solutions have helped optimize our operations to meet the demand for these mission-critical applications.”
About Quantori
Quantori is transforming life sciences and healthcare with the power of digital IT. The company develops bespoke IT and data science solutions for accelerating research and drug discovery and improving healthcare delivery. Quantori combines data engineering and advanced analytics with scientific knowledge management and best-in-class software engineering to help life science and healthcare companies successfully achieve their digital transformations with greater speed and agility. Learn more at www.quantori.com and connect on social media @Twitter , @LinkedIn , and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210720005589/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES Announces Extraordinary General Meeting of Shareholders15.5.2026 08:30:00 CEST | Press release
SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Extraordinary General Meeting of SES, Société Anonyme, to be held at the Company's registered office at Château de Betzdorf, L-6815 Betzdorf (the "Company"), Luxembourg, on Wednesday 17 June 2026 at 3:00 p.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Cancellation of shares purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024, in accordance therewith and pursuant thereto - Reduction of the share capital in accordance with article 450-5 of the law of 10 August 1915 on commercial companies, as amended, by forty-four million nine hundred ten thousand seven hundred eighty euro (EUR 44,910,780) through the cancellation of thirty-five million nine hundred and twenty-eight thousand six hundred and twenty-four (35,928,624) shares divided into (i) twenty-three million nine hundred and fifty-two thousand four hun
Experian Partners With ServiceNow to Scale Trusted Decisioning to Agentic AI15.5.2026 08:00:00 CEST | Press release
New global long‑term partnership embeds Experian’s Ascend capabilities directly into ServiceNow workflows, transforming client operations Experian, the global data and technology company, and ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today unveil a new global multi-year partnership which harnesses the power of autonomous AI agents across platforms, helping businesses make faster and smarter decisions at scale. Through this partnership, autonomous AI agents can gain the ability to act faster, and more consistently, starting with employee onboarding, third-party risk management and model life cycle governance use cases. A major challenge for global organisations adopting agentic AI is achieving scale, with deployments often constrained by a lack of trusted data. In fact, industry research shows that data limitations are the primary barrier for eight in ten organisations. By connecting trusted intelligence directly into enterprise workflows, this partnership e
Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet15.5.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of two global Phase III clinical trials evaluating the efficacy and safety of its novel β-lactamase inhibitor nacubactam (development code: OP0595), have been published in The Lancet. The article is entitled “---Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial” (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00596-9/fulltext) Integral-1 is a global, double-blind, randomized Phase III trial (jRCT2031230075) in patients with complicated urinary tract infection or acute uncomplicated pyelonephritis that compared the efficacy and safety of nacubactam co-administered with either cefepime or aztreonam versus imipenem-c
Boomi Teams up With Gong to Bring Revenue AI to Boomi Agentstudio14.5.2026 18:00:00 CEST | Press release
Gong's revenue AI is now natively available in the Boomi Enterprise Platform Boomi, the data activation company for AI, today announced a collaboration withGong, the leader in Revenue AI, to bring revenue signals captured in Gong natively into the Boomi Enterprise Platform. This collaboration enables enterprises to establish an active data foundation designed to transform customer conversations into coordinated, automated actions across systems and functions enterprise-wide with Boomi Agentstudio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514443012/en/ Boomi Teams Up with Gong to Bring Revenue AI to Boomi Agentstudio Gong goes beyond capturing deal activity to surface real-time insights into risk, buyer intent, competitive dynamics, and key engagement signals. That intelligence moves from conversation to coordinated action, flowing across CRM, ERP, product, and operational systems with the governance and security tha
Xsolla and Skich Announce Strategic Partnership to Bring Merchant of Record Payments to an Alternative Mobile Game Marketplace14.5.2026 18:00:00 CEST | Press release
Partnership Enables Developers To Monetize Games On The Skich Store With Xsolla Handling Payments, Tax Compliance, And Commerce Infrastructure Xsolla, a leading global video game commerce company, today announced a strategic partnership with Skich, an alternative mobile game marketplace operating on iOS in the EU under Apple's Digital Markets Act provisions and on Android globally. Under the agreement, Xsolla will serve as Merchant of Record for in-app purchases and paid game sales distributed through the Skich Store. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514867730/en/ Graphic: Xsolla Skich serves as an alternative to traditional mobile storefronts, offering developers a way to reach players outside platform-controlled distribution channels. The partnership with Xsolla enables Skich to offer a fully compliant payment and commerce layer, with Xsolla managing payment processing, tax collection, refunds, and regulat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom